Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The FDA has granted approval to Can-Fite BioPharma to conduct a Phase I study with its second pipeline liver cancer drug, CF102.
Subscribe to our email newsletter
A Phase I study in healthy volunteers will be conducted in the US by a clinical research organization (CRO) in a Phase I unit. Can-Fite estimates that this study will be initiated in the first quarter of 2008, and results should be published by the end of the first quarter of 2008.
Pnina Fishman, CEO of Can-Fite, said: “The initiation of this study is a substantial progress for the company, since it reflects the expansion of our development pipeline with a drug for additional indication. There are almost no competing therapies for liver cancer and there is a market need because the response rate of these patients to curative chemotherapy is very low. Our drug works through a unique mechanism that allows liver cancer cells to be targeted and attacked with high specificity.”